Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.95 is 699% above its 4-year average of 0.12, near the low end of its 4-year range (-2.16–8.59).
As of the fiscal period ended Tuesday, June 30, 2026. 10.14% above its 12-month average of 0.87.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.95.
DEBT TO EQUITY RATIO
0.95
DEBT TO EQUITY RATIO AVG TTM
0.87
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+10.14%
CURRENT VS 3Y AVG
+22951.82%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+766.20%
vs the sector median at left
Market Cap
$720866.00
Debt to Equity Ratio
0.04
TTM Avg
0.05
3Y Avg
0.14
5Y Avg
0.20
Market Cap
$563178.00
Debt to Equity Ratio
0.88
TTM Avg
2.46
3Y Avg
1.03
5Y Avg
0.63
Market Cap
$530678.00
Debt to Equity Ratio
N/A
TTM Avg
0.24
3Y Avg
0.17
5Y Avg
0.11
Market Cap
$827005.00
Debt to Equity Ratio
0.00
TTM Avg
0.17
3Y Avg
1.36
5Y Avg
1.55
Market Cap
$840509.00
Debt to Equity Ratio
0.00
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$844430.00
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.04
Market Cap
$850879.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$867372.00
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
1.83
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CDT Equity Inc. (CDT) | $678241.00 | 0.95 | 0.87 | 0.00 | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $720866.00 | 0.04 | 0.05 | 0.14 | 0.20 |
| HCW Biologics Inc. (HCWB)vs › | $563178.00 | 0.88 | 2.46 | 1.03 | 0.63 |
| VivoSim Labs, Inc. (VIVS)vs › | $530678.00 | N/A | 0.24 | 0.17 | 0.11 |
| Ridgetech, Inc. (RDGT)vs › | $827005.00 | 0.00 | 0.17 | 1.36 | 1.55 |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | 0.00 | 0.07 | 0.05 | 0.04 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $844430.00 | 0.01 | 0.03 | 0.06 | 0.04 |
| Bone Biologics Corporation (BBLG)vs › | $850879.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sunshine Biopharma, Inc. (SBFM)vs › | $867372.00 | 0.02 | 0.04 | 0.04 | 1.83 |
| XORTX Therapeutics Inc. (XRTX)vs › | $484571.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.95
Current Ratio
2.14
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.95 |
| 2026-03-29 | 1.05 |
| 2025-12-31 | 1.02 |
| 2025-09-28 | 0.44 |
| 2025-06-29 | 0.59 |
| 2025-03-30 | 1.07 |
| 2024-12-31 | -1.10 |
| 2024-09-29 | -0.29 |
| 2024-06-30 | -0.23 |
| 2024-03-31 | -0.42 |
| 2023-12-31 | -2.16 |
| 2023-09-30 | -0.91 |
| 2023-06-30 | 0.04 |
| 2023-03-31 | 0.02 |
| 2022-12-31 | -0.20 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 8.59 |
